Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Michael Bristow to Polymorphism, Genetic

This is a "connection" page, showing publications Michael Bristow has written about Polymorphism, Genetic.

 
Connection Strength
 
 
 
2.796
 
  1. Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF, Felker GM, Liggett SB, O'Connor CM, Bristow MR. Dose Response of ?-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018 08; 11(8):e002210.
    View in: PubMed
    Score: 0.490
  2. Aleong RG, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR. Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013 Aug; 1(4):338-344.
    View in: PubMed
    Score: 0.347
  3. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb; 6(1):137-43.
    View in: PubMed
    Score: 0.333
  4. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010 Jan; 3(1):21-8.
    View in: PubMed
    Score: 0.267
  5. Sharkey SW, Maron BJ, Nelson P, Parpart M, Maron MS, Bristow MR. Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. J Cardiol. 2009 Feb; 53(1):53-7.
    View in: PubMed
    Score: 0.248
  6. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11288-93.
    View in: PubMed
    Score: 0.213
  7. Taylor MR, Bristow MR. The emerging pharmacogenomics of the beta-adrenergic receptors. Congest Heart Fail. 2004 Nov-Dec; 10(6):281-8.
    View in: PubMed
    Score: 0.189
  8. Chevalier P, Roy P, Bessi?re F, Morel E, Ankou B, Morgan G, Halder I, London B, Minobe WA, Slavov D, Delini?re A, Bochaton T, Paganelli F, Lesavre N, Boiteux C, Mansourati J, Maury P, Clerici G, Winum PF, Huebler SP, Carroll IA, Bristow MR. Impact of Neuroeffector Adrenergic Receptor Polymorphisms on Incident Ventricular Fibrillation During Acute Myocardial Ischemia. J Am Heart Assoc. 2023 03 21; 12(6):e025368.
    View in: PubMed
    Score: 0.169
  9. Sucharov CC, Nakano SJ, Slavov D, Schwisow JA, Rodriguez E, Nunley K, Medway A, Stafford N, Nelson P, McKinsey TA, Movsesian M, Minobe W, Carroll IA, Taylor MRG, Bristow MR. A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium. J Am Coll Cardiol. 2019 03 19; 73(10):1173-1184.
    View in: PubMed
    Score: 0.128
  10. O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and ?1, a2C adrenergic receptor polymorphisms. PLoS One. 2012; 7(10):e44324.
    View in: PubMed
    Score: 0.082
  11. Dockstader K, Nunley K, Karimpour-Fard A, Medway A, Nelson P, Port JD, Liggett SB, Bristow MR, Sucharov CC. Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the ?1-adrenergic receptor. Physiol Genomics. 2011 Dec 05; 43(23):1294-306.
    View in: PubMed
    Score: 0.076
  12. Murphy GA, Fiuzat M, Bristow MR. Targeting heart failure therapeutics: a historical perspective. Heart Fail Clin. 2010 Jan; 6(1):11-23.
    View in: PubMed
    Score: 0.068
  13. Taylor MR, Bristow MR. Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure. Novartis Found Symp. 2006; 274:73-83; discussion 83-9, 152-5, 272-6.
    View in: PubMed
    Score: 0.051
  14. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005 Sep; 2(9):475-83.
    View in: PubMed
    Score: 0.050
  15. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation. 2003 Mar 04; 107(8):1100-2.
    View in: PubMed
    Score: 0.042
  16. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001 May; 33(5):887-905.
    View in: PubMed
    Score: 0.037
  17. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993 Oct 30; 342(8879):1073-5.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)